Baltimore, Maryland
Cancer clinical trials in Baltimore, MD
223 cancer studies are recruiting participants at sites in Baltimore as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Baltimore at a glance
- 223 studies are recruiting at a site in Baltimore.
- By phase: Early Phase 1 (3), Phase 1 (25), Phase 1/2 (22), Phase 2 (52), Phase 2/3 (4), Phase 3 (67), No phase (18), Observational (32). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (102), university, hospital or other (102), government (19).
- By research area: Lung Cancer (67), Breast Cancer (52), Prostate Cancer (41), Lymphoma (37), Pancreatic Cancer (21), Melanoma (5).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Baltimore
Basic details from each study's public record (the 30 most recently updated of 223). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- Johns Hopkins Kimmel Cancer Center
- Registry record
- NCT05696626 · updated
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Johns Hopkins University/Sidney Kimmel Cancer Center · Mercy Medical Center · Sinai Hospital of Baltimore
- Registry record
- NCT06058377 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study site
- Sidney Kimmel Comprehensive Cancer Center
- Registry record
- NCT06638307 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- MedStar Franklin Square Medical Center ( Site 0031) · MedStar Good Samaritan Hospital ( Site 0079)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mercy Medical Center - Baltimore ( Site 0015)
- Registry record
- NCT06966700 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Lung cancer studies recruiting in Baltimore
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Teligene US
- Study site
- University of Maryland Medical Center
- Registry record
- NCT05168566 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Johns Hopkins University/Sidney Kimmel Cancer Center · University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT06287775 · updated
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- MedStar Franklin Square Medical Center ( Site 0033)
- Registry record
- NCT06780098 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Greater Baltimore Medical Center · Johns Hopkins University/Sidney Kimmel Cancer Center · Kaiser Permanente-Woodlawn Medical Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT06096844 · updated
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- OSE Immunotherapeutics
- Study site
- Ascension Saint Agnes Hospital
- Registry record
- NCT06472245 · updated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT06498635 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Johns Hopkins University
- Registry record
- NCT07020221 · updated
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07291037 · updated
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- University of Maryland School of Medicine
- Registry record
- NCT07472517 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Prostate cancer studies recruiting in Baltimore
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT04423211 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Baltimore Veterans Affairs Medical Center ( Site 0069) · Greenebaum Comprehensive Cancer Center ( Site 0049)
- Registry record
- NCT06136624 · updated
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT05691465 · updated
Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe
- Phase 1
- Ages 40 to 75
- Male participants
- Sponsor
- Johns Hopkins University
- Study site
- Johns Hopkins Hospital
- Registry record
- NCT07271017 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Lymphoma studies recruiting in Baltimore
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT06724237 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT06337318 · updated
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Registry record
- NCT07003295 · updated
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Nuvalent Inc.
- Study site
- John Hopkins University
- Registry record
- NCT05384626 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Baltimore, MD on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Baltimore
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Phase 2
- Ages 12 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108)
- Registry record
- NCT04924075 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Johns Hopkins University
- Registry record
- NCT07644559 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.
Ask about studies near Baltimore
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Maryland
All Maryland locations
388 studies recruiting across 33 cities.
Bethesda
142 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections